Concordance of PD-L1 expression and CD8+ TIL intensity between NSCLC and synchronous brain metastases

Authors

  • Sebnem Batur Department of Pathology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey https://orcid.org/0000-0001-6577-8970
  • Onur Dulger Department of Pathology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey https://orcid.org/0000-0002-1155-7790
  • Sermin Durak Department of Pathology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey https://orcid.org/0000-0001-6741-4345
  • Perran Fulden Yumuk Department of Internal Medicine, Division of Medical Oncology, Pendik Education and Research Hospital, School of Medicine, Marmara University, Istanbul, Turkey https://orcid.org/0000-0001-8650-299X
  • Hale Basak Caglar Department of Radiation Oncology, Medipol University, Istanbul, Turkey
  • Emine Bozkurtlar Department of Pathology, School of Medicine, Marmara University, Istanbul, Turkey https://orcid.org/0000-0002-1034-9236
  • Suheyla Bozkurt Department of Pathology, School of Medicine, Marmara University, Istanbul, Turkey https://orcid.org/0000-0002-5947-947X
  • Ebru Tastekin Department of Pathology, Medical Faculty, Trakya University, Edirne, Turkey
  • Irfan Cicin Department of Internal Medicine, Division of Medical Oncology, Trakya University, Edirne, Turkey https://orcid.org/0000-0002-7584-3868
  • Rengin Ahiskali Department of Pathology, School of Medicine, Marmara University, Istanbul, Turkey
  • Rashad Rzazade Department of Radiation Oncology, Anatolia Health Center, Gebze, Turkey
  • Asli Cakir Department of Internal Medicine, Division of Medical Oncology, Medipol University, Istanbul, Turkey https://orcid.org/0000-0003-0128-6947
  • Buge Oz Department of Pathology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey https://orcid.org/0000-0003-3201-1313

DOI:

https://doi.org/10.17305/bjbms.2019.4474

Keywords:

Programmed death-ligand 1, non-small-cell lung cancer, NSCLC, tumor immunology, PD-L1, brain metastasis, CD8 lymphocytes, tumor infiltrating lymphocytes, TILs

Abstract

Programmed death-ligand 1 (PD-L1) is suggested to be a predictive biomarker in non-small-cell lung carcinoma (NSCLC). However, the differential expression of PD-L1 in primary lung tumor vs. synchronous metastases, especially brain metastasis (BM), remains unclear. This study assessed the concordance of PD-L1 expression on tumor cells and tumor-infiltrating lymphocytes (TILs) and CD8+ TIL intensity between primary lung tumors and synchronous BMs from 24 NSCLC patients. PD-L1, CD3, and CD8 positivity was determined by immunohistochemistry (IHC). PD-L1 scoring was based on the proportion of tumor cells with membranous expression of PD-L1 and the cutoff values <1%, 1–49%, and ≥50%. CD3 and CD8 positivity in TILs was evaluated semi-quantitatively and the proportion of CD3+/CD8+ TILs was determined. PD-L1 expression on tumor cells and TILs was evaluated in relation to CD3+/CD8+ TIL proportions and the intensity of CD8+ TILs between the paired primary lung and BM tissues. In the primary lung tumors, PD-L1 positivity was observed in 25%, 37.5%, and 37.5% cases for the cutoff values <1%, 1–49%, and ≥50%, respectively. PD-L1 expression on tumor cells was strongly correlated between the paired primary lung and BM tissues, in all cutoff groups. However, PD-L1 expression on TILs and the proportion of CD3+/CD8+ TILs were not strongly correlated in all three groups between the paired primary lung tumors and BMs. The intensity of CD8+ TILs was concordant in only 54.16% of the paired primary lung tumors and BMs. This study showed a high concordance of PD-L1 expression in neoplastic cells between primary NSCLC and synchronous BMs.

Downloads

Download data is not yet available.
Concordance of PD-L1 expression and CD8+ TIL intensity between NSCLC and synchronous brain metastases

Downloads

Additional Files

Published

03-08-2020

How to Cite

1.
Concordance of PD-L1 expression and CD8+ TIL intensity between NSCLC and synchronous brain metastases. Biomol Biomed [Internet]. 2020 Aug. 3 [cited 2024 Apr. 20];20(3):329-35. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/4474